Reuters logo
BRIEF-Ironwood and Allergan report topline phase IIB data for abdominal pain in non-constipation subtypes of IBS
December 22, 2016 / 12:16 PM / a year ago

BRIEF-Ironwood and Allergan report topline phase IIB data for abdominal pain in non-constipation subtypes of IBS

Dec 22 (Reuters) - Ironwood Pharmaceuticals Inc

* Ironwood Pharmaceuticals - Co, Allergan plan to engage with U.S. Fda to discuss next steps for advancing CR2 into a phase IIB dose-ranging clinical trial

* Ironwood Pharma - Co, Allergan are pursuing patent protection for CR1 and CR2 that, if issued, is expected to provide patent coverage into mid-2030’s

* Press Release - Ironwood and Allergan report topline phase IIB data supporting further investigation of linaclotide colonic release-2 (CR2) for abdominal pain in non-constipation subtypes of IBS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below